Loading clinical trials...

Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer

Randomized Phase II Study of Suramin and Docetaxel Versus Docetaxel in Non-Small Cell Lung Cancer After Failure of First-Line Chemotherapy

NCT01671332•University of Wisconsin, Madison

View on ClinicalTrials.gov

Summary

Detailed Description

The overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second and third line settings. Secondary objectives include: * To compare response rate of patients in both treatment arms * To compare overall survival of patients in both treatment arms * To compare toxicity in both treatment arms * To determine whether the survival benefit from suramin is associated with reduced M-phase entry in peripheral blood lymphocytes

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Pathologically proven diagnosis of non-small cell lung cancer
•Documented disease progression after first-line chemotherapy for non-small cell lung cancer
•Stable and treated CNS metastasis is allowed
•Radiation must be completed at least 2 weeks prior to starting protocol treatment
•Major surgery must be completed at least 4 weeks prior to starting protocol treatment
•ECOG performance status 0-2
•Sexually active patients must use adequate contraception
•Adequate bone marrow function
•Adequate renal function
•Adequate liver function

Exclusion Criteria

•Severe hypersensitivity reaction to docetaxel
•Pre-existing grade 3 or 4 neuropathy
•Women who are pregnant or breastfeeding
•Uncontrolled intercurrent illness
•Receipt of 3 or more prior chemotherapy regimens

Locations (2)

University of Wisconsin Carbone Comprehensive Cancer Center

Madison, Wisconsin, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Key Dates

Start Date

June 1, 2012

Primary Completion Date

June 11, 2015

Completion Date

June 16, 2016

Last Updated

May 12, 2020

Enrollment

ACTUAL participants

Conditions

Carcinoma, Non Small Cell Lung

Interventions

Docetaxel

DRUG

Suramin

DRUG

Docetaxel

DRUG

Locally Advanced NSCLC Hyperfractionated RT

NCT03128008

Carcinoma, Non Small Cell Lung (NSCLC)

View study

COMPLETEDPHASE2

Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer

NCT00798720

Carcinoma, Non Small Cell Lung

View study

COMPLETEDPHASE2

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

NCT00548093

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 12, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer

Inclusion Criteria

Exclusion Criteria

Locally Advanced NSCLC Hyperfractionated RT

Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer